Comparison of interval and Monte Carlo simulation for the prediction of postprandial glucose under uncertainty in type 1 diabetes mellitus

2011 ◽  
Vol 104 (3) ◽  
pp. 325-332 ◽  
Author(s):  
R. Calm ◽  
M. García-Jaramillo ◽  
J. Bondia ◽  
M.A. Sainz ◽  
J. Vehí
Keyword(s):  
Diabetes Mellitus ◽  
Monte Carlo Simulation ◽  
Monte Carlo ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Postprandial Glucose

scholarly journals Increasing the protein quantity in a meal results in dose-dependent effects on postprandial glucose levels in individuals with Type 1 diabetes mellitus

2017 ◽  
Vol 34 (6) ◽  
pp. 851-854 ◽  
Author(s):  
M. A. Paterson ◽  
C. E. M. Smart ◽  
P. E. Lopez ◽  
P. Howley ◽  
P. McElduff ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Postprandial Glucose ◽  
Glucose Levels ◽  
Dose Dependent

Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device

2004 ◽  
Vol 20 (S2) ◽  
pp. S24-S31 ◽  
Author(s):  
Bego�a Manuel-y-Keenoy ◽  
Jan Vertommen ◽  
Pascale Abrams ◽  
Luc Van Gaal ◽  
Ivo De Leeuw ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Glucose Monitoring ◽  
Postprandial Glucose ◽  
Monitoring Device

scholarly journals DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Qixian Wang ◽  
Min Long ◽  
Hua Qu ◽  
Rufei Shen ◽  
Rui Zhang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Meta Analysis ◽  
Postprandial Glucose ◽  
Cochrane Library ◽  
Therapeutic Effects ◽  
Dipeptidyl Peptidase 4 ◽  
Positive Effects

Objective. Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM). This study aims to review the outcomes of these existing studies and to discuss the therapeutic effects of DPP-4 inhibitors on T1DM. Methods. We thoroughly searched the Medline, Embase, PubMed, and Cochrane Library databases and ClinicalTrials.gov for studies concerning the use of DPP-4 inhibitors in patients with T1DM. Results. In preclinical trials, DPP-4 inhibitors improved the pathogenesis of T1DM. However, only a portion of the studies showed potential efficacy regarding clinical glycemic control and other clinical parameters. From this meta-analysis, pooled data from 5 randomized controlled trials revealed that the additional use of DPP-4 inhibitors resulted in a greater decrease in glycated hemoglobin A1c (HbA1c) levels (0.07%, 95% CI (−0.37%–0.23%)) than insulin monotherapy, although the decrease was not significant. A small decrease in postprandial glucose or insulin consumption was confirmed. Conclusion. Although DPP-4 inhibitors may be beneficial for T1DM, existing studies do not strongly support these positive effects in clinical practice. Further optimized clinical trials are needed.

Sign in / Sign up

Export Citation Format

Share Document